Journal of Infection and Public Health (Feb 2020)
Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)
- J. Van Wyk,
- F. Ajana,
- F. Bisshop,
- S. De Wit,
- Y. Osiyemi,
- J. Portilla,
- J. Routy,
- C. Wyen,
- M. Ait-Khaled,
- M. Nascimento,
- K. Pappa,
- R. Wang,
- J. Wright,
- A. Tenorio,
- B. Wynne,
- M. Aboud,
- M. Gartland,
- K. Smith,
- Y. El-Bahy
Affiliations
- J. Van Wyk
- ViiV Healthcare
- F. Ajana
- Centre Hospitalier de Tourcoing
- F. Bisshop
- Holdsworth House Medical Brisbane
- S. De Wit
- CHU St-Pierre
- Y. Osiyemi
- Triple O Research Institute PA
- J. Portilla
- Hospital General Universitario de Alicante
- J. Routy
- McGill University Health Centre
- C. Wyen
- Praxis am Ebertplatz
- M. Ait-Khaled
- ViiV Healthcare
- M. Nascimento
- ViiV Healthcare
- K. Pappa
- ViiV Healthcare
- R. Wang
- ViiV Healthcare
- J. Wright
- GlaxoSmithKline
- A. Tenorio
- ViiV Healthcare
- B. Wynne
- ViiV Healthcare
- M. Aboud
- ViiV Healthcare
- M. Gartland
- ViiV Healthcare
- K. Smith
- ViiV Healthcare
- Y. El-Bahy
- GlaxoSmithKline; Corresponding author.
- Journal volume & issue
-
Vol. 13,
no. 2
p. 349
